New oral medication shows promise for more quickly treating MRSA skin infections, researchers find

Share this article:

A new oral antibiotic may effectively treat MRSA-related skin infections more quickly than the only oral drug currently approved, according to research published Wednesday in the Journal of the American Medical Association.

Researchers led by Philippe Prokocimer, M.D., the chief medical officer at Trius Therapeutics Inc., compared the effectiveness of tedizolid phosphate with linezolid. Linezolid is the only oral medication currently approved to treat certain skin infections caused by methicillin-resistant Staphylococcus Aureus (MRSA).

The acute bacterial skin and skin structure infections (SSSIs) caused by MRSA can be fatal, and there have been outbreaks of linezolid-resistant strains of MRSA, the researchers noted.

In a 667-person trial carried out in North America, Latin America and Europe, participants received either a daily dose of tedizolid phosphate for six days or a dose of linezolid every 12 hours for 10 days.

Based on clinical outcomes, the researchers determined the newer drug is “clinically noninferior” to linezolid.

Nursing homes experience a high rate of community-associated MRSA, according to a study in the March issue of Infection Control and Hospital Epidemiology.

Share this article:
close

Next Article in News

More in News

Bill addressing admission status receives praise

A bill that would require hospitals to give patients a formal notice of their admission status has received strong support from healthcare associations.

Increased 'bed taxes' on nursing facilities warrant stricter federal oversight, report states

States have been increasingly taxing skilled nursing facilities and other healthcare providers to fund Medicaid in recent years, and federal authorities should look more closely at this trend, according to a government report released Tuesday.

Last chance: Tech Awards deadline arrives

Last chance: Tech Awards deadline arrives

There are hours left for innovative long-term care providers to enter the third annual McKnight's Excellence in Technology Awards. Submissions will be accepted until the stroke of midnight tonight.